The subjects will be implanted with the ARTUS® medical device and then be followed up to 2 years post-implantation, with the primary endpoints measured at 3-month post-implantation. Safety and Clinical performance outcomes will be measured for each subject at baseline (before implantation) and post-implantation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
The subjects will be implanted by the ARTUS Artificial Urinary Sphincter (AUS). The device will be activated 6 weeks after surgery and the tightening will be adjusted by the investigators in order to reach continence.
Cochin Hospital, APHP
Paris, France
Tenon Hospital, APHP
Paris, France
Adverse Device Effect Incidence
all adverse device effects (device and/or procedure related) occurring from the implantation up to the 3 months post-operative visit, with their occurrence, severity, and nature. These events will be analyzed and classified using the Clavien-Dindo classification grading system.
Time frame: 3 months after implantation
Adverse Events Incidence
all adverse events (including adverse device effect) occurring peri-operatively, 30 days after implantation and at 3, 6, 12 and 24-months post-operative with their occurrence, severity, and nature. All adverse events will be analyzed and classified using the Clavien-Dindo classification grading system
Time frame: Day 30, 3 months, 6 months, 12 months and 24 months after implantation
Revision Rate
Proportion of subjects with a revision of the Artificial Urinary Sphincter
Time frame: 30 days, 3 months, 6 months, 12 months and 24 months after implantation
Explantation Rate
Proportion of subjects with a definitive explantation of the Artificial Urinary Sphincter
Time frame: Day 30, 3 months, 6 months, 12 months and 24 months after implantation
Evolution of Renal Function
Measure of the serum creatinine
Time frame: Baseline, Day 1
Evolution of the pain
Measure of the pain using a 10-point numerical scale (from 0 no pain to 10 the maximum pain)
Time frame: Day 1, Day 45, 3 months, 6 months, 12 months and 24 months after implantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Evolution of uroflowmetry
measure of the voided urine per unit of time, the voided volume and the maximum flow rate
Time frame: Baseline, 3 months after implantation
Bladder Drainage
measure of the post-void residual volume
Time frame: Baseline, Day 1, 3 months, 6 months, 12 months and 24 months after implantation
Device Deficiency
Number of device deficiencies
Time frame: Implantation, Day 1, Day 45, 3 months, 6 months, 12 months, 24 months after implantation
Pad Weight Test
Measure of the daily urine loss in pads during 3 consecutive days
Time frame: Baseline, 3 months, 6 months, 12 months and 24 months after implantation
Pads Usage
Number of pads used per day
Time frame: Baseline, Day 45, 3 months, 6 months, 12 months and 24 months after -implantation
Evolution of Stress Urinary Symptoms
Evolution of the International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form (ICIQ-UI SF). The score ranges from 0 (no impact) to 21 (maximal impact).
Time frame: Baseline, 3 months, 6 months, 12 months and 24 months after implantation
Evolution of Urinary Symptoms
Evolution of the Urinary Symptom Profile (USP). The score ranges from 0 (no symptom) to 9 (maximal symptoms) for the subscore linked to the Stress Urinary Incontinence; from 0 (no symptom) to 21 (maximal symptoms) for the subscore linked to the overactive bladder; from 0 (no symptom) to 9 (maximal symptoms) for the subscore linked to the dysuria.
Time frame: Baseline, 3 months, 6 months, 12 months, 24 months after implantation